Soleno reports Q4 net loss $11.3M; NDA for DCCR in PWS on track for mid-2024

SOLENO THERAPEUTICS INC

Cash and equivalents $169.7M at Dec 31, 2023, boosted by $129M Oct 2023 offering and $43.1M warrant exercises.
R&D expenses rose to $8.7M (Q4 2023) vs $3.8M (Q4 2022); full-year $25.2M vs $15.3M.
Corrected G&A for Q4 2023: $4.1M vs previously reported $4.4M; full-year $13.5M vs $9.8M.
Positive top-line data from C602 withdrawal: primary endpoint met (p=0.0022); DCCR well-tolerated.
Leadership additions: Meredith Manning as CCO, Dairine Dempsey VP Europe, Lauren Budesheim VP HR.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SOLENO THERAPEUTICS INC reported the fourth quarter and year ended December 31, 2023 results: net income Net loss was approximately $11.3 million, or $0.33 per basic and diluted share, for the quarter ended December 31, 2023,, EPS $0.33 per basic and diluted share (Q4 2023); $2.36 per basic and diluted share (FY 2023).

Period: the fourth quarter and year ended December 31, 2023
Net income: Net loss was approximately $11.3 million, or $0.33 per basic and diluted share, for the quarter ended December 31, 2023,
EPS: $0.33 per basic and diluted share (Q4 2023); $2.36 per basic and diluted share (FY 2023)
Result: reported results

Exact text from the filing

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

SOLENO THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-24-061288

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.